Home » Stocks » SESN

Sesen Bio, Inc. (SESN)

Stock Price: $3.73 USD -0.02 (-0.53%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $3.74 +0.01 (0.27%) Jul 30, 7:58 PM
Market Cap 659.36M
Revenue (ttm) 15.55M
Net Income (ttm) -119.47M
Shares Out 157.03M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $3.73
Previous Close $3.75
Change ($) -0.02
Change (%) -0.53%
Day's Open 3.73
Day's Range 3.65 - 3.84
Day's Volume 3,423,406
52-Week Range 0.91 - 4.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

4 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and its partner in G...

1 week ago - Business Wire

Sesen Bio Inc (NASDAQ: SESN) participated in a Late-Cycle Meeting with the FDA regarding the marketing application seeking approval for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (...

2 weeks ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

2 weeks ago - Business Wire

Looking to invest in penny stocks in July? Here's some tips to help out The post Is Making Money With Penny Stocks Possible in July 2021?

Other stocks mentioned: CYRN, INUV, JFU, MTC, SINT
3 weeks ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the g...

4 weeks ago - Business Wire

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?

Other stocks mentioned: GTE, IAG, METX, MUX, PIRS, UEC, VTGN
1 month ago - PennyStocks

Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.

Other stocks mentioned: CFMS, ELYS, MNMD, NXE, PTIX, SENS
1 month ago - InvestorPlace

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?

Other stocks mentioned: ANPC, PIRS
1 month ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the g...

1 month ago - Business Wire

Which biotech penny stocks are on your watchlist as Covid comes to an end? The post Top Biotech Penny Stocks to Buy?

Other stocks mentioned: ENZC, ZOM
1 month ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

1 month ago - Business Wire

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and In...

Other stocks mentioned: ADXS, TTOO, TYME
2 months ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

2 months ago - Business Wire

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

Other stocks mentioned: PIRS, PTIX, TTOO
2 months ago - PennyStocks

These biotech penny stocks and former stocks under $5 are turning heads in the analyst community right now The post 3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today appeared first on P...

Other stocks mentioned: GTBP, SCPS
2 months ago - PennyStocks

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...

Other stocks mentioned: ITRM, MRKR, TELL, VTGN
2 months ago - PennyStocks

Making a penny stocks watchlist for June? Take a look at these 3 The post Top Penny Stocks to Buy Right Now?

Other stocks mentioned: FRSX, IZEA, PHUN
2 months ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

2 months ago - Business Wire

Hot penny stocks to watch this month. The post Penny Stocks To Watch For May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: ALF, TRVG
2 months ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the g...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it w...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that on Fr...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

4 months ago - Business Wire

The FDA accepted the company's filing for approval of Vicineum in treating bladder cancer.

5 months ago - The Motley Fool

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in the...

5 months ago - Benzinga

Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-musc...

5 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

5 months ago - Business Wire

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...

5 months ago - Business Wire

An analyst is very bullish about the biotech stock.

6 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that ...

6 months ago - Business Wire

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced subm...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favo...

7 months ago - Business Wire

Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceut...

7 months ago - Business Wire

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

8 months ago - Business Wire

About SESN

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2014
CEO
Thomas Cannell
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
SESN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Sesen Bio stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 87.67% from the latest price.

Price Target
$7.00
(87.67% upside)
Analyst Consensus: Strong Buy